Novartis, Roche, AstraZeneca, Sanofi Winners In 2013: China Big Pharma Roundup
This article was originally published in PharmAsia News
Impacted by compliance issues, Big Pharma’s growth slowed in China. However, Novartis, Roche, AstraZeneca and Sanofi actually gained market share for the year.
You may also be interested in...
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.